Header Logo

PREMAL LULLA

TitleAssociate Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Medicine
Address1102 BATES
Houston, TX 77030
vCardDownload vCard
    Other Positions
    TitleAssociate Professor
    InstitutionBaylor College of Medicine
    DepartmentCenter for Cell & Gene Therapy
    DivisionCenter for Cell & Gene Therapy


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Hill LC, Rouce RH, Wu M, Wang T, Ma R, Zhang H, Mehta B, Lapteva N, Mei Z, Smith TS, Yang L, Srinivasan M, Burkhardt PM, Ramos CA, Lulla PD, Arredondo M, Grilley B, Heslop HE, Brenner MK, Mamonkin M, Hill LC, Rouce RH, Wu MJ, Wang T, Ma R, Zhang H, Mehta B, Lapteva N, Mei Z, Smith TS, Yang L, Srinivasan M, Burkhardt PM, Ramos CA, Lulla P, Arredondo M, Grilley B, Heslop HE, Brenner MK, Mamonkin M. Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024 Mar 28; 143(13):1231-1241. PMID: 38145560; PMCID: PMC10997912.
      Citations:    Fields:    Translation:HumansCells
    2. Mathioudaki A, Wang X, Sedloev DN, Huth R, Kamal A, Hundemer M, Liu Y, Vasileiou S, Lulla PD, M?ller-Tidow C, Dreger P, Luft T, Sauer T, Schmitt M, Zaugg JB, Pabst C, Mathioudaki A, Wang X, Sedloev D, Huth R, Kamal A, Hundemer M, Liu Y, Vasileiou S, Lulla P, M?ller-Tidow C, Dreger P, Luft T, Sauer T, Schmitt M, Zaugg JB, Pabst C. The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature. Blood. 2024 Mar 28; 143(13):1269-1281. PMID: 38197505; PMCID: PMC10997908.
      Citations: 1     Fields:    Translation:HumansCells
    3. Leung WK, Torres Chavez AG, French-Kim M, Shafer P, Mamonkin M, Hill LC, Kuvalekar M, Velazquez Y, Watanabe A, Watanabe N, Hoyos V, Lulla PD, Leen AM. Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia. Blood. 2024 Jan 19. PMID: 38241630.
      Citations:    Fields:    
    4. Kapadia CD, Rosas G, Thakkar SG, Wu M, Torrano V, Wang T, Grilley BJ, Heslop HE, Ramos CA, Goodell MA, Lulla PD. Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy. Cytotherapy. 2024 Mar; 26(3):261-265. PMID: 38149948; PMCID: PMC10922117.
      Citations:    Fields:    Translation:Humans
    5. Badr H, Rouce R, Scheurer ME, Lulla P, Mims M, Reddy P. Bringing CAR T?cell therapy trials to underserved populations. Cancer Cell. 2023 12 11; 41(12):2007-2010. PMID: 37890490.
      Citations:    Fields:    Translation:Humans
    6. Vasileiou S, Hill L, Kuvalekar M, Workineh AG, Watanabe A, Velazquez Y, Lulla S, Mooney K, Lapteva N, Grilley BJ, Heslop HE, Rooney CM, Brenner MK, Eagar TN, Carrum G, Grimes KA, Leen AM, Lulla P. Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients. Haematologica. 2023 Jul 01; 108(7):1840-1850. PMID: 36373249; PMCID: PMC10316279.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    7. Quach DH, Lulla P, Rooney CM. Banking on virus-specific T cells to fulfill the need for?off-the-shelf cell therapies. Blood. 2023 02 23; 141(8):877-885. PMID: 36574622; PMCID: PMC10023738.
      Citations:    Fields:    Translation:HumansCells
    8. Pfeiffer T, Tzannou I, Wu M, Ramos C, Sasa G, Martinez C, Lulla P, Krance RA, Scherer L, Ruderfer D, Naik S, Bocchini C, Fraser IP, Patel B, Ward D, Wang T, Heslop HE, Leen AM, Omer B. Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting. Clin Cancer Res. 2023 01 17; 29(2):324-330. PMID: 36628536; PMCID: PMC9843433.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    9. Lulla PD, Brenner M. Emerging Challenges to Cellular Therapy of Cancer. Cancer J. 2023 Jan-Feb 01; 29(1):20-27. PMID: 36693154; PMCID: PMC9881841.
      Citations:    Fields:    Translation:HumansCells
    10. Maneix L, Iakova P, Moree SE, Hsu JI, Mistry RM, Stossi F, Lulla P, Sun Z, Sahin E, Yellapragada SV, Catic A. Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 (HDAC3) Stabilization and Chromatin Condensation. Cancer Res Commun. 2022 12; 2(12):1693-1710. PMID: 36846090; PMCID: PMC9949381.
      Citations:    Translation:HumansCells
    11. Bajgain P, Torres Chavez AG, Balasubramanian K, Fleckenstein L, Lulla P, Heslop HE, Vera J, Leen AM. Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand-Expressing Solid Tumors. Cancer Immunol Res. 2022 11 02; 10(11):1370-1385. PMID: 36122411; PMCID: PMC9633434.
      Citations:    
    12. Hoyos V, Vasileiou S, Kuvalekar M, Watanabe A, Tzannou I, Velazquez Y, French-Kim M, Leung W, Lulla S, Robertson C, Foreman C, Wang T, Bulsara S, Lapteva N, Grilley B, Ellis M, Osborne CK, Coscio A, Nangia J, Heslop HE, Rooney CM, Vera JF, Lulla P, Rimawi M, Leen AM. Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer. Ther Adv Med Oncol. 2022; 14:17588359221107113. PMID: 35860837; PMCID: PMC9290161.
      Citations:    
    13. Steffin DHM, Muhsen IN, Hill LC, Ramos CA, Ahmed N, Hegde M, Wang T, Wu M, Gottschalk S, Whittle SB, Lulla PD, Mamonkin M, Omer B, Rouce RH, Heczey A, Metelitsa LS, Grilley BJ, Robertson C, Torrano V, Lapteva N, Gee AP, Rooney CM, Brenner MK, Heslop HE. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24. PMID: 35325065; PMCID: PMC9346960.
      Citations:    Fields:    Translation:HumansCells
    14. Naik S, Vasileiou S, Tzannou I, Kuvalekar M, Watanabe A, Robertson C, Lapteva N, Tao W, Wu M, Grilley B, Carrum G, Kamble RT, Hill L, Krance RA, Martinez C, Tewari P, Omer B, Gottschalk S, Heslop HE, Brenner MK, Rooney CM, Vera JF, Leen AM, Lulla PD. Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant?in patients with ALL. Blood. 2022 04 28; 139(17):2706-2711. PMID: 35134127; PMCID: PMC9053698.
      Citations: 1     Fields:    Translation:Humans
    15. Lulla PD. CAR T cells and autologous transplantation can coexist for DLBCL. Blood. 2022 03 03; 139(9):1266-1267. PMID: 35238887; PMCID: PMC8900274.
      Citations:    Fields:    Translation:HumansCells
    16. Friend BD, Muhsen IN, Patel S, Hill LC, Lulla P, Ramos CA, Pingali SR, Kamble RT, John TD, Salem B, Bhar S, Doherty EE, Craddock J, Sasa G, Wu M, Wang T, Martinez C, Krance RA, Heslop HE, Carrum G. Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplant. 2022 04; 57(4):579-585. PMID: 35105965.
      Citations:    Fields:    Translation:Humans
    17. Hamadani M, Gopal AK, Pasquini M, Kim S, Qiu X, Ahmed S, Lazaryan A, Bhatt VR, Daly A, Lulla P, Ciurea S, Gauthier J, Agrawal V, Grover NS, Lekakis L, Modi D, Dahi PB, Herr MM, Johnson PC, Hashmi H, Hematti P, Locke FL. Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. Blood Adv. 2022 01 25; 6(2):486-494. PMID: 34673903; PMCID: PMC8791562.
      Citations: 1     Fields:    Translation:Humans
    18. Hill LC, Lulla PD. COVID-specific T's may offset therapeutically endangered B's. Blood. 2022 01 06; 139(1):12-13. PMID: 34989773; PMCID: PMC8734939.
      Citations: 1     Fields:    Translation:HumansCells
    19. Al Hadidi S, Dongarwar D, Salihu HM, Kamble RT, Lulla P, Hill LC, Carrum G, Ramos CA, Heslop HE, Usmani SZ. Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study. Leuk Lymphoma. 2021 12; 62(13):3256-3263. PMID: 34278937; PMCID: PMC8962656.
      Citations: 1     Fields:    Translation:Humans
    20. Streck BP, Naufal G, Carrum G, Hill L, Heslop HE, Ramos CA, Kamble R, Cohen M, East K, Sena M, Lulla P. Demographic and Clinical Donor Characteristics as Predictors of Total Nucleated Cell Concentrations in Harvested Marrow Products. Transplant Cell Ther. 2021 09; 27(9):785.e1-785.e6. PMID: 34082160.
      Citations:    Fields:    Translation:HumansCells
    21. Lulla PD, Naik S, Vasileiou S, Tzannou I, Watanabe A, Kuvalekar M, Lulla S, Carrum G, Ramos CA, Kamble R, Hill L, Randhawa J, Gottschalk S, Krance R, Wang T, Wu M, Robertson C, Gee AP, Chung B, Grilley B, Brenner MK, Heslop HE, Vera JF, Leen AM. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021 05 13; 137(19):2585-2597. PMID: 33270816; PMCID: PMC8120140.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    22. Linder K, Lulla P. Myelodysplastic syndrome and immunotherapy novel to next in-line treatments. Hum Vaccin Immunother. 2021 08 03; 17(8):2602-2616. PMID: 33941042; PMCID: PMC8475606.
      Citations: 1     Fields:    Translation:Humans
    23. Maneix L, Sweeney MA, Lee S, Iakova P, Moree SE, Sahin E, Lulla P, Yellapragada SV, Tsai FTF, Catic A. The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma. Cancers (Basel). 2021 Feb 17; 13(4). PMID: 33671345; PMCID: PMC7922145.
      Citations: 2     
    24. Vasileiou S, Lulla PD, Tzannou I, Watanabe A, Kuvalekar M, Callejas WL, Bilgi M, Wang T, Wu MJ, Kamble R, Ramos CA, Rouce RH, Zeng Z, Gee AP, Grilley BJ, Vera JF, Bollard CM, Brenner MK, Heslop HE, Rooney CM, Leen AM, Carrum G. T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 05 01; 39(13):1415-1425. PMID: 33507803; PMCID: PMC8274795.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    25. Lulla PD, Tzannou I, Vasileiou S, Carrum G, Ramos CA, Kamble R, Wang T, Wu M, Bilgi M, Gee AP, Mukhi S, Chung B, Wang L, Watanabe A, Kuvalekar M, Jeong M, Li Y, Ketkar S, French-Kim M, Grilley B, Brenner MK, Heslop HE, Vera JF, Leen AM. The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. Sci Transl Med. 2020 07 29; 12(554). PMID: 32727914.
      Citations: 11     Fields:    Translation:Humans
    26. Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, Wang T, Shea TC, Rooney CM, Dittus C, Park SI, Gee AP, Eldridge PW, McKay KL, Mehta B, Cheng CJ, Buchanan FB, Grilley BJ, Morrison K, Brenner MK, Serody JS, Dotti G, Heslop HE, Savoldo B. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol. 2020 11 10; 38(32):3794-3804. PMID: 32701411; PMCID: PMC7655020.
      Citations: 57     Fields:    Translation:HumansCTClinical Trials
    27. Leung WK, Workineh A, Mukhi S, Tzannou I, Brenner D, Watanabe N, Leen AM, Lulla P. Evaluation of cyclin A1-specific T cells as a potential treatment for acute myeloid leukemia. Blood Adv. 2020 Jan 28; 4(2):387-397. PMID: 31985805; PMCID: PMC6988407.
      Citations: 3     Fields:    Translation:HumansCells
    28. Torres Chavez A, McKenna MK, Canestrari E, Dann CT, Ramos CA, Lulla P, Leen AM, Vera JF, Watanabe N. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity. J Immunother Cancer. 2019 11 28; 7(1):330. PMID: 31779709; PMCID: PMC6883585.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    29. Lulla PD, Mamonkin M, Brenner MK. Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. Cancer J. 2019 May/Jun; 25(3):199-207. PMID: 31135527; PMCID: PMC6602906.
      Citations: 2     Fields:    Translation:Humans
    30. Vasileiou S, Turney AM, Kuvalekar M, Mukhi SS, Watanabe A, Lulla P, Ramos CA, Naik S, Vera JF, Tzannou I, Leen AM. Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections. Haematologica. 2020 01; 105(1):235-243. PMID: 31004020; PMCID: PMC6939529.
      Citations: 7     Fields:    Translation:HumansCells
    31. Hill L, Lulla P, Heslop HE. CAR-T cell Therapy for Non-Hodgkin Lymphomas: A New Treatment Paradigm. Adv Cell Gene Ther. 2019 Jul; 2(3). PMID: 31777773; PMCID: PMC6880960.
      Citations: 3     
    32. Atilla E, Atilla PA, Mo F, Tashiro H, Srinivasan M, Lulla P, Rouce RH, Ramos CA, Brenner MK, Mamonkin M, Gomes-Silva D, Cabral JMS. CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia. Mol Ther. 2019 01 02; 27(1):272-280. PMID: 30391141; PMCID: PMC6318703.
      Citations: 41     Fields:    Translation:HumansAnimalsCells
    33. Bajgain P, Tawinwung S, D'Elia L, Sukumaran S, Watanabe N, Hoyos V, Lulla P, Brenner MK, Leen AM, Vera JF. CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer. 2018 05 10; 6(1):34. PMID: 29747685; PMCID: PMC5944113.
      Citations: 39     Fields:    Translation:Humans
    34. Lulla PD, Hill LC, Ramos CA, Heslop HE. The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2018 May; 16(5):375-386. PMID: 29851933; PMCID: PMC6469642.
      Citations: 12     Fields:    Translation:HumansCells
    35. Tzannou I, Nicholas SK, Lulla P, Aguayo-Hiraldo PI, Misra A, Martinez CA, Machado AA, Orange JS, Piedra PA, Vera JF, Leen AM. Immunologic Profiling of Human Metapneumovirus for the Development of Targeted Immunotherapy. J Infect Dis. 2017 09 15; 216(6):678-687. PMID: 28934427; PMCID: PMC5853664.
      Citations: 14     Fields:    Translation:HumansCells
    36. Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, Carrum G, Sasa G, Lulla P, Watanabe A, Kuvalekar M, Gee AP, Wu MF, Liu H, Grilley BJ, Krance RA, Gottschalk S, Brenner MK, Rooney CM, Heslop HE, Leen AM, Omer B. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 01; 35(31):3547-3557. PMID: 28783452; PMCID: PMC5662844.
      Citations: 135     Fields:    Translation:HumansCellsCTClinical Trials
    37. Aguayo-Hiraldo PI, Arasaratnam RJ, Tzannou I, Kuvalekar M, Lulla P, Naik S, Martinez CA, Piedra PA, Vera JF, Leen AM. Characterizing the Cellular Immune Response to Parainfluenza Virus 3. J Infect Dis. 2017 07 15; 216(2):153-161. PMID: 28472480; PMCID: PMC5853958.
      Citations: 12     Fields:    Translation:HumansCells
    38. Tashiro H, Sauer T, Shum T, Parikh K, Mamonkin M, Omer B, Rouce RH, Lulla P, Rooney CM, Gottschalk S, Brenner MK. Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213. PMID: 28676343; PMCID: PMC5589064.
      Citations: 61     Fields:    Translation:HumansAnimalsCells
    39. Lulla P, Heslop HE. Fall of the mutants: T cells targeting BCR-ABL. Blood. 2017 02 02; 129(5):539-540. PMID: 28153834; PMCID: PMC5290991.
      Citations: 4     Fields:    Translation:HumansCells
    40. Lulla P, Ramos CA. Expanding Accessibility to CD19-CAR T Cells: Commercializing a "Boutique" Therapy. Mol Ther. 2017 01 04; 25(1):8-9. PMID: 28129132; PMCID: PMC5363183.
      Citations: 1     Fields:    Translation:HumansCells
    41. Lulla P, Heslop HE. Checkpoint inhibition and cellular immunotherapy in lymphoma. Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):390-396. PMID: 27913506; PMCID: PMC6142511.
      Citations: 3     Fields:    Translation:HumansCells
    42. Brammer JE, Lulla P, Lynch GR. Retrospective review of extra-pulmonary small cell carcinoma and prognostic factors. Int J Clin Oncol. 2014 Oct; 19(5):822-8. PMID: 24122253.
      Citations: 8     Fields:    Translation:Humans
    43. Kowalkowski MA, Mims MP, Amiran ES, Lulla P, Chiao EY. Effect of immune reconstitution on the incidence of HIV-related Hodgkin lymphoma. PLoS One. 2013; 8(10):e77409. PMID: 24098586; PMCID: PMC3788758.
      Citations: 10     Fields:    Translation:HumansCells
    44. Lulla PD, Brammer JE, Bandeali S, Lynch GR. Sustained complete remission of metastatic hepatocellular carcinoma with single agent sorafenib. J Gastrointest Cancer. 2013 Mar; 44(1):98-101. PMID: 23054578.
      Citations: 2     Fields:    Translation:Humans
    45. Lulla P, Bandeali S, Baker K. Fatal paraneoplastic systemic leukocytoclastic vasculitis as a presenting feature of chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S14-6. PMID: 22035741.
      Citations: 4     Fields:    Translation:Humans
    46. Brammer JE, Lulla P, Lynch GR. Complete remission in a patient with metastatic mixed adenocarcinoma/extrapulmonary small cell carcinoma of the prostate. Int J Clin Oncol. 2011 Dec; 16(6):722-5. PMID: 21347630.
      Citations: 8     Fields:    Translation:Humans
    LULLA's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (185)
    Explore
    _
    Co-Authors (54)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _